MX2021000403A - Composicion de derivados de aminoacido gamma triciclico fusionados y la preparacion de la misma. - Google Patents

Composicion de derivados de aminoacido gamma triciclico fusionados y la preparacion de la misma.

Info

Publication number
MX2021000403A
MX2021000403A MX2021000403A MX2021000403A MX2021000403A MX 2021000403 A MX2021000403 A MX 2021000403A MX 2021000403 A MX2021000403 A MX 2021000403A MX 2021000403 A MX2021000403 A MX 2021000403A MX 2021000403 A MX2021000403 A MX 2021000403A
Authority
MX
Mexico
Prior art keywords
amino acid
acid derivative
composition
fused tricyclic
preparation therefor
Prior art date
Application number
MX2021000403A
Other languages
English (en)
Inventor
Pangke Yan
Feng Peng
Xuanmiao Zhang
Hua Mao
Juanjuan Deng
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of MX2021000403A publication Critical patent/MX2021000403A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona una composición farmacéutica de derivados de aminoácido gamma tricíclico fusionados y el uso del mismo. La composición farmacéutica incluye: (i) un compuesto que tiene una estructura representada por la fórmula (I) o una sal farmacéuticamente aceptable del mismo, como un material activo, en una cantidad de 1% hasta 45% en peso; (ii) opcionalmente uno o más rellenos en una cantidad de 50% hasta 95% en peso; (iii) opcionalmente uno o más agentes lubricantes en una cantidad de 0.1% hasta 5.5% en peso; y la suma de los porcentajes en peso de todos los componentes es 100%, en donde la sal farmacéuticamente aceptable del compuesto de la fórmula (I) tiene una estructura como sigue. (ver Fórmula).
MX2021000403A 2018-07-12 2019-07-12 Composicion de derivados de aminoacido gamma triciclico fusionados y la preparacion de la misma. MX2021000403A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810756863 2018-07-12
PCT/CN2019/095856 WO2020011257A1 (zh) 2018-07-12 2019-07-12 一种稠合三环γ-氨基酸衍生物的组合物及其制备

Publications (1)

Publication Number Publication Date
MX2021000403A true MX2021000403A (es) 2021-03-25

Family

ID=69142171

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000403A MX2021000403A (es) 2018-07-12 2019-07-12 Composicion de derivados de aminoacido gamma triciclico fusionados y la preparacion de la misma.

Country Status (13)

Country Link
US (1) US20210186909A1 (es)
EP (1) EP3822252A4 (es)
JP (1) JP7222063B2 (es)
KR (1) KR102515847B1 (es)
CN (1) CN112384494A (es)
AU (1) AU2019302611B2 (es)
BR (1) BR112021000398A2 (es)
CA (1) CA3106382C (es)
EA (1) EA202190126A1 (es)
MX (1) MX2021000403A (es)
TW (1) TWI808217B (es)
WO (1) WO2020011257A1 (es)
ZA (1) ZA202100181B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115916744A (zh) * 2020-07-20 2023-04-04 四川海思科制药有限公司 一种稠合三环γ-氨基酸衍生物的缓释药物制剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223072D0 (en) * 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
CN1827095A (zh) * 2006-04-14 2006-09-06 北京润德康医药技术有限公司 一种以普瑞巴林为活性成分的药用组合物及其制备方法、用途
US8932629B2 (en) * 2006-10-27 2015-01-13 Fmc Corporation Co-processed microcrystalline cellulose and sugar alcohol as an excipient for tablet formulations
PT2192109E (pt) * 2007-09-28 2013-12-09 Daiichi Sankyo Co Ltd Derivado de -aminoácido bicíclico
WO2010079668A1 (ja) 2009-01-08 2010-07-15 第一三共株式会社 オレフィン化合物
CN107848952B (zh) 2015-12-31 2021-04-09 四川海思科制药有限公司 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用
KR102539234B1 (ko) * 2016-04-07 2023-06-02 에스케이케미칼 주식회사 은행잎 추출물을 포함하는 경구용 서방 제제
JP7001679B2 (ja) * 2016-09-14 2022-02-04 四川海思科制▲薬▼有限公司 縮合３環γ－アミノ酸誘導体及びその製造方法、並びに医薬における応用

Also Published As

Publication number Publication date
KR102515847B1 (ko) 2023-03-29
TW202012362A (zh) 2020-04-01
CA3106382C (en) 2023-11-07
AU2019302611A1 (en) 2021-02-25
EA202190126A1 (ru) 2021-06-30
KR20210028680A (ko) 2021-03-12
JP7222063B2 (ja) 2023-02-14
US20210186909A1 (en) 2021-06-24
TWI808217B (zh) 2023-07-11
BR112021000398A2 (pt) 2021-04-06
CN112384494A (zh) 2021-02-19
EP3822252A4 (en) 2021-11-17
AU2019302611B2 (en) 2022-02-17
EP3822252A1 (en) 2021-05-19
WO2020011257A1 (zh) 2020-01-16
ZA202100181B (en) 2022-06-29
CA3106382A1 (en) 2020-01-16
JP2021525789A (ja) 2021-09-27

Similar Documents

Publication Publication Date Title
AU2021323253A8 (en) Heterocyclic GLP-1 agonists
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
CR20200532A (es) Compuestos de heteroarilo tetracíclicos
MX2022008066A (es) Compuestos triciclicos sustituidos.
JOP20210241A1 (ar) مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان
MX2022006475A (es) Compuestos triciclicos sustituidos.
MX2022009524A (es) Agonistas heterociclicos de glp-1.
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2013003036A (es) Derivados de pirazina como bloqueadores de enac.
MX2019011491A (es) Formulaciones de niraparib.
SG10201407538WA (en) Intravenous formulations of neurokinin-1 antagonists
MX2013007909A (es) Formulaciones inmunosupresoras.
JOP20210004A1 (ar) عوامل تحلّل مستقبلات الإستروجين الانتقائية
MX2022006736A (es) Combinacion de un antagonista del receptor lpa1 de azetidina con pirfenidona y/o nintedanib para su uso en el tratamiento de enfermedades fibroticas.
EA202192845A1 (ru) Новые композиции, содержащие мелфлуфен
MX2022015886A (es) Derivados de amidopirimidona.
ZA202108263B (en) Imidazolonylquinoline compounds and therapeutic uses thereof
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
WO2007064620A3 (en) Compositions comprising a combination of ccr5 and cxcr4 antagonists
SA519401614B1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
WO2021055425A3 (en) Functionalized heterocycles as antiviral agents
MX2022016263A (es) Derivados de ciclobutil-urea.
MX2021003739A (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.